OPEN

Effect of Enhanced Recovery After Surgery on the Prognosis of Patients With Hip Fractures: A Systematic Review and Meta-Analysis



Ruiqi Zhu[®] = Fengqiao Yang[®] = Caiying Li[®] = Hongxia Zhu[®] = Lu Lin, PhD[®] = Xin Zhao, PhD[®]

BACKGROUND:	Hip fractures, predominantly occurring in the elderly, are a significant public health concern due to associated morbid- ity, disability, and mortality. Prolonged bed rest following the fracture often leads to complications, further threatening patient health. Enhanced recovery after surgery, a modern approach to postoperative care, is being explored for its potential to improve outcomes and quality of life in hip fracture patients.
OBJECTIVE:	This study investigates the impact of enhanced recovery after surgery on hip fracture patients.
METHODS:	In this systematic review, we addressed the PICO question: Does the enhanced recovery after surgery program reduce 1-year mortality, readmissions, and postoperative pain and improve Harris Hip Score compared with tradi- tional care in elderly hip fracture patients? We searched key databases and gray literature and analyzed outcomes through a meta-analysis using RevMan, Stata, and the Newcastle–Ottawa Scale for quality assessment.
RESULTS:	Nine studies involving 10,359 patients were included. Compared with the control group, the enhanced recovery after surgery group showed significant reduction in length of stay (mean difference [MD] = -2.00 ; 95% confidence interval [CI] [$-2.87, -1.14$]; $p < .0001$) and overall complication rate (risk ratio [RR] = 0.76 ; 95% CI [$0.67, 0.85$]; $p < .0001$), with a lower delirium rate (RR = 0.42 ; 95% CI [$0.26, 0.68$]; $p = .004$). No significant differences were observed in Harris Hip Score, pain score, 1-year mortality, readmission rate, or incidences of urinary tract infection, respiratory tract infection, and deep vein thrombosis.
CONCLUSION:	Enhanced recovery after surgery is associated with reduced length of stay, complication rate, and delirium rate in hip fracture patients.
KEY WORDS:	Complication rate, Enhanced recovery after surgery, ERAS, Hip fracture, Length of stay
	Cite as: Zhu, R., Yang, F., Li, C., Zhu, H., Lin, L., & Zhao, X. (2023). Effect of enhanced recovery after surgery on the prognosis of patients with hip fractures: A systematic review and meta-analysis. <i>Journal of Trauma Nursing, 30</i> (5), 271-281. https://doi.org/10.1097/JTN.000000000000741

Hip fractures, common in the older population, are serious injuries with high morbidity, disability, and mortality rates. The increasing trend in hip fracture incidences, coupled with population aging, highlights a global health concern. Hip fractures impact patients' daily life and independence (Alexiou et al., 2018), with global incidences exceeding 1.7 million annually and are projected to reach 6.3 million by 2050 (Anderson et al., 2009). Mortality rates are reported to

Dates: Submitted February 13, 2023; Revised July 01, 2023; Accepted, July 02, 2023.

Author Affiliations: Departments of Nursing (Zhu, Drs Lin and Zhao) and Orthopedic (Zhu), the First Affiliated Hospital of Soochow University, Suzhou, China; and School of Nursing, Medical College of Soochow University, Suzhou, China (Zhu, Yang, Li, Drs Lin and Zhao).

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Ruiqi Zhu, Fengqiao Yang, Caiying Li, and Hongxia Zhu. The first draft of the manuscript was written by Ruiqi Zhu, Fengqiao Yang, Caiying Li, Hongxia Zhu, Lu Lin, Xin Zhao, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. vary between 6.1% to 8.7% within 30 days and 21% to 30% within a year of the fracture (Bai et al., 2020; Liu et al., 2021).

Surgery is the primary treatment, yet recovery is often slow for older patients due to underlying health conditions, causing anxiety and poor rehabilitation compliance (Balfour et al., 2022). Perioperative care is essential for maximizing surgical benefits and hastening recovery.

This work was supported by Soochow University undergraduate Extracurricular Academic Research Fund Project (KY20220134A) and the Humanities and Social Sciences Youth Foundation, Ministry of Education of the People's Republic of China (Grant No. 20YJCZH088). The funders have no role in study design, data collection, analysis, interpretation, and decision to submit for publication.

The authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (WWW. JOURNALOFTRAUMANURSING.COM).

Correspondence: Xin Zhao, PhD, the First Affiliated Hospital of Soochow University, Medical College of Soochow University, No. 188 Shizi St, Suzhou 215006, China (mumu011120@163.com) or Lu Lin, PhD, the First Affiliated Hospital of Soochow University, Medical College of Soochow University, No. 188 Shizi St, Suzhou 215006, China (linlu@suda.edu.cn).

KEY POINTS

- Hip fractures in older adults often lead to significant postoperative complications, with traditional care models often falling short in optimizing patient recovery.
- This study indicates that ERAS-based perioperative care can enhance patient prognosis, including shorter hospital stays, reduced postoperative pain, and lower complication rates.
- ERAS protocols can be incorporated into care strategies for older adults with hip fractures to improve surgical outcomes and patient experience.
- Despite promising results, the study highlights the need for more comprehensive, well-designed studies to further validate these findings, especially in developing countries.
- Study results should be interpreted cautiously due to limitations such as potential confounding factors and lack of exploration of subgroup interactions.

Enhanced recovery after surgery (ERAS), proposed by Kehlet (1997), is a comprehensive nursing approach comprising preoperative, intraoperative, and postoperative measures, including preoperative nutritional support, analgesia, fluid management, and early rehabilitation (Eriksson et al., 2012). ERAS has shown effectiveness in reducing postoperative mortality, shortening length of stay (LOS), and lowering complication rates (Gomez et al., 2019). However, the impact of ERAS on the prognosis of hip surgery patients lacks high-quality evidence. Research shows conflicting results: researchers have noted shortened LOS for total hip arthroplasty patients but not for hip fracture patients (Proudfoot et al., 2017), whereas other researchers found no significant difference in mortality and readmission rates between ERAS and standard care (Haugan et al., 2017).

High LOS in hip fractures represents a significant public health issue linked to increased complications, readmission rates, and mortality (Husted et al., 2010). The Harris Hip Score (HHS) is a widely used measure of joint function posthip fracture. Delirium, a common postoperative complication in older hip fracture patients, can increase medical costs and postoperative mortality (Jiang et al., 2021).

OBJECTIVE

The aim of this study was to systematically evaluate the effect of ERAS on patients with hip fractures, using outcome indicators such as HHS, LOS, pain score, 1-year mortality, readmission rate, and the incidence of complications.

PICO QUESTION

- Population: Elderly patients with hip fractures
- Intervention: ERAS programs
- Comparator: Traditional perioperative care
- Outcomes: One-year mortality, readmission rate, HHS, postoperative pain score, LOS, incidence of postoperative complications

Among elderly patients presenting with hip fractures, should ERAS programs be implemented compared with traditional perioperative care to reduce 1-year mortality, readmission rates, postoperative pain scores, LOS and incidence of postoperative complications, and to improve HHS?

METHODS

Search Strategy

We performed a systematic review of related literature in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines (Page et al., 2021). To enhance the comprehensiveness and systematic nature of our search strategy, we conducted searches on various databases, including Embase, PubMed, Web of Science, CINAHL, and Cochrane libraries, from database inception to June 15, 2022, with the language limited to English. In addition, we searched MEDLINE via the Ovid platform, Scopus, PsycINFO, ClinicalTrials.gov, and China National Knowledge Infrastructure (CNKI), among others. The search limits and conditions of each database were adjusted to ensure the accuracy and consistency of the search results. Figure 1 contains the string used for the initial search. Reference lists of related articles were also searched manually. In our team, each author independently reviews all retrieved article titles and

("Hip Fractures"[MeSH] OR "hip fracture"[tiab] OR "fracture of hip"[tiab]) AND ("Enhanced Recovery After Surgery"[MeSH] OR "ERAS"[tiab] OR "fast-track surgery"[tiab] OR "accelerated recovery"[tiab]) AND ("Perioperative Care"[MeSH] OR "traditional care"[tiab] OR "usual care"[tiab]) AND ("Mortality"[MeSH] OR "readmission"[tiab] OR "Harris Hip Score"[tiab] OR "pain score"[tiab] OR "length of stay"[tiab] OR "postoperative complications"[tiab]) AND ("Aged"[MeSH] OR "elderly"[tiab] OR "older adults"[tiab]) AND ("Humans"[MeSH])

Figure 1. Search string with MeSH terms.

abstracts and filters them according to preset inclusion and exclusion criteria.

After the preliminary screening, the screening results were discussed by all the authors to confirm the final inclusion of studies. During the discussion stage, if there were differences in the inclusion or exclusion of a study, the following measures were taken to resolve the differences. First, the full text of the article was reviewed and carefully checked to determine whether it met the inclusion and exclusion criteria. After the full text review, a discussion was held to share views and reasons. If no consensus could be reached after the discussion, third-party experts were consulted to review the divergent articles independently. The third party made the final decision on whether to include the divergent study.

Inclusion and Exclusion Criteria

Design and Study

Studies published in English that examined the effect of ERAS on the prognosis of patients with hip fractures were included. The exclusion criteria included case reports, editorials, animal experiments, commentaries, reviews, and articles with insufficient data for quantitative analysis.

This review established specific criteria for inclusion and exclusion. The population under consideration is comprised individuals who have experienced a hip fracture without regard to demographic factors such as age, gender, race, or baseline characteristics. The intervention employed for treatment and rehabilitation was the ERAS regimen. Compared with the control group who received conventional perioperative nursing, the intervention group was given perioperative ERAS care. The study's findings included at least one outcome pertaining to the prognosis of patients, such as the duration of hospitalization, HHS, pain levels, 1-year mortality rates, rehospitalization rates, and the occurrence of complications. There was no time limit imposed on the inclusion of studies. Studies published in English that investigated the impact of ERAS on the prognosis of individuals who had sustained a hip fracture were eligible. The exclusion criteria for this study encompassed nonoriginal research works, including case reports, editorials, animal experiments, reviews, and meta-analyses.

Participants

Older patients (aged > 60 years) of all genders who underwent hip fracture surgery and received ERAS were included. Those diagnosed with advanced malignancy, cachexia, and systemic organ metastases were excluded.

Exposure/Intervention

The exposed/intervention group was given perioperative ERAS care, including the following:

1. Preoperative patient education, psychological counseling;

- 2. Optimization of anesthesia;
- 3. Simplified preoperative routine bowel preparation;
- 4. Perioperative nutrition management;
- 5. Intraoperative nursing: In addition to routine care, rewarming blankets were used and intraoperative fluid infusion was maintained at 37 °C;
- 6. Rational use of drainage tubes and catheters;
- 7. Postoperative analgesia;
- 8. Early postoperative standard functional exercise;
- 9. Perioperative fluid therapy

Comparison

The nonexposed/control group received conventional perioperative nursing. The ERAS protocol is a collection of multidisciplinary strategies designed to optimize perioperative patient care and enhance patient rehabilitation. Although many ERAS strategies are regarded as standard practice in contemporary surgical nursing, these strategies may not be completely implemented or adhered to in conventional perioperative nursing. Traditional perioperative care includes prolonged fasting, excessive intravenous infusion, absence of early activity and rehabilitation, and more stringent postoperative pain management. In our study, the control group received conventional perioperative care, so they may not have reaped the full benefits of the ERASpromoted strategies to enhance patient recovery. In contrast, the intervention group received care based on the ERAS, which included individualized perioperative care strategies such as early nutrition, reduced intravenous infusion, multimodal analgesia, and early rehabilitation.

Outcomes

Outcomes included at least one of the following measures: The primary outcomes HHS, LOS, pain score, 1-year mortality, and readmission rate; the secondary outcomes included overall complication rate and incidence of deep vein thrombosis (DVT), urinary tract infection, delirium, and respiratory tract infection.

Study Selection

According to the inclusion and exclusion criteria mentioned earlier, the study selection process was conducted independently by two reviewers (Z. R. Q. and Y. F. Q.), including screening titles, abstracts, and full texts.

Data Extraction

The two reviewers independently extracted data from the eligible studies, and any disagreement was discussed with a third reviewer to reach a consensus. The data extracted from the literature were as follows: first author, publication year, country, age, sex, study design, sample size, type of fractures, and outcome measures.

Copyright © 2023 Society of Trauma Nurses.

The longest follow-up data on outcome measures of each study were extracted.

Quality Assessment

The Newcastle–Ottawa Scale (NOS) (Stang, 2010) was used to assess the methodological quality of the included studies in terms of selection, comparability, and outcome, with a maximum score of nine. Scores seven or more showed a low risk of bias, scores from four to six demonstrated a medium risk of bias, and scores less than four indicated a high risk of bias.

Statistical Analysis

For continuous outcomes (LOS, HHS, and pain score), the mean difference (MD) with 95% confidence interval (CI) was calculated, whereas for dichotomous outcomes (the 1-year mortality, readmission rate, complication rate), the risk ratio (RR) was calculated. Heterogeneity was assessed by the Cochran's Q test and Higgins I² test; if the test results showed statistical homogeneity (p > .100, $I^2 < 50\%$), the fixed-effect model was used to merge data for analysis; on the contrary, if the test results showed statistical heterogeneity $(p \le .100, I^2 \ge 50\%)$, the random-effect model was used, and sensitivity analysis was conducted by eliminating individual studies one by one and observing the difference between the combined effect size and the total effect size of the remaining studies. Publication bias was evaluated by funnel plot analysis and Egger's linear regression test (only for the number of studies > 4). All tests were two-tailed, and statistical significance was defined as p < .050 (except for the heterogeneity test, which was considered statistically significant at p < .100). All analyses were performed in RevMan 5.3 and Stata 15.1.

RESULTS

Search Results and Study Characteristics

The initial literature search produced 7,131 records. After removing duplicates, 6,925 articles were screened by title and abstract and 6,885 were excluded. Following this step, full texts of 40 articles were read, of which nine (Gomez et al., 2019; Haugan et al., 2017; Kang et al., 2019; Li et al., 2020; Liu et al., 2017; Macfie et al., 2012; Pedersen et al., 2008; Pollmann et al., 2019; Sura-Amonrattana et al., 2021), involving 10,359 participants, met the inclusion criteria and were eventually included (Figure 2). The distributions of age, sex, and types of fractures were similar among the studies. Study types included prospective cohort studies, retrospective cohort studies, randomized controlled trials, and quasi-experimental studies. The studies were conducted in China (n = 2), France (n = 1), England (n = 1), Norway (n = 2), Thailand (n = 1), America (n = 1), and Denmark (n = 1) (Table 1).

Quality Assessment

After scoring the studies based on the NOS, a low risk of bias was observed in all studies. The minimum score was seven, and the maximum was nine (Table 2).

Primary Outcomes

Length of Stay

There were eight studies (Gomez et al., 2019; Haugan et al., 2017; Kang et al., 2019; Liu et al., 2017; Macfie et al., 2012; Pedersen et al., 2008; Pollmann et al., 2019; Sura-Amonrattana et al., 2021) with available LOS data (Figure 3A). A random-effects model was applied (p < .0001, I² = 98%), and a significant reduction in the mean LOS was found for the ERAS patients compared with the control group (MD = -2.00; 95% CI [-2.87, -1.14]; p < .0001). The sensitivity analysis of the total effect was conducted by eliminating individual studies one by one. The results showed little difference from the original total effect, suggesting that the results of this study were stable.

Harris Hip Score

Two (Kang et al., 2019; Li et al., 2020) of the nine studies assessed the HHS (n = 184) (Figure 3B). Meta-analysis showed no significant difference in HHS between ERAS and control arms (MD = 4.20; 95% CI [-3.65, 12.05]; p = .29), with high heterogeneity ($I^2 = 95\%$, p > .0001). Because of the limited number of included studies (only two), although the heterogeneity was very high, we did not conduct a sensitivity analysis.

Pain Score

Two (Kang et al., 2019; Li et al., 2020) of the nine studies (n = 184) had assessed pain scores (Figure 3C). Meta-analysis showed a significant difference in pain scores between the two studies (MD = -0.95; 95% CI [-1.34, -0.57]; p < .00001) with low heterogeneity (p = .73, $I^2 = 0$).

One-Year Mortality

Five of the nine studies (n = 4,941) had assessed 1-year mortality (Gomez et al., 2019; Haugan et al., 2017; Pedersen et al., 2008; Pollmann et al., 2019; Sura-Amonrattana et al., 2021) (Figure 3D). Metaanalysis showed no significant difference in 1-year mortality across all five studies (RR = 0.99; 95% CI [0.90, 1.10]; p = .91) with low heterogeneity (I² = 27%, p = .24).

274 www.journaloftraumanursing.com




Figure 2. Flow diagram of study selection.

Readmission Rate

There were six studies (Gomez et al., 2019; Haugan et al., 2017; Kang et al., 2019; Liu et al., 2017; Pollmann et al., 2019; Sura-Amonrattana et al., 2021) with available data on readmission rate (Figure 3E). A fixed-effects model was applied, as the heterogeneity was not significant (p = .31, $I^2 = 16\%$). A significant reduction in the mean readmission rate was not found in the ERAS patients compared with the control group (RR = 1.02; 95% CI [0.94, 1.11]; p = .66).

Secondary Outcomes

Overall Complication Rate

Four of the nine studies (n = 3,154) assessed the overall complication rate (Kang et al., 2019; Liu et al., 2017; Macfie et al., 2012; Pedersen et al., 2008) (see Supplemental Digital Content Figure 4a, available at: http://links.lww.com/JTN/A116). Meta-analysis showed a significant difference in overall complication rate across all four studies (RR = 0.76; 95% CI [0.67,

0.85]; p < .0001) with low heterogeneity (p = .21, $I^2 = 33\%$).

Urinary Tract Infection Rate

Five of the nine studies assessed urinary tract infection rate (Gomez et al., 2019; Kang et al., 2019; Macfie et al., 2012; Pedersen et al., 2008; Sura-Amonrattana et al., 2021) (see Supplemental Digital Content Figure 4b, available at: http://links.lww.com/JTN/A116). Meta-analysis showed no significant difference in urinary tract infection rate across all five studies (RR = 0.81; 95% CI [0.38, 1.75]; p = .60) with high heterogeneity (p = .008, $I^2 = 75\%$). The sensitivity analysis of the total effect was conducted by eliminating individual studies one by one. The results showed little difference from the original total effect, suggesting that the results of this study were stable.

Respiratory Tract Infection Rate

Five of the nine studies assessed respiratory tract infection rate (Gomez et al., 2019; Kang et al.,

Andres Dublished				Characterist	Characteristics of Study Population	opulation	s of Study Population	5	200	0 4 0 1		
Auulor, rublicauoli Year	Country	Sample	Sample Size (N)	Age (V	(Years)	Male/F	Male/Female	Follow-up	Type of Fracture	Measures	Study Design	Outcomes
Gomez et al., 2019	France	27	27	84.5 (8.7)	85.0 (8.5)	7 M/20 F	7 M/20 F	1 year	Peritrochanteric fracture	2, 4	Prospective cohort study	LOS, readmission rates, 1-year mortality, overall complication rate, specific complication rate, DVT, delirium rate
Haugan et al., 2017	Norway	1,032	788	83.1	83.1	298 M/734 F	214 M/574 F	1 year	Hip fracture	4, 7, 9	Retrospective cohort studies	Mortality, readmission rates, LOS
Kang et al., 2019	China	20	50	77.81 (8.14)	78.32 (8.24)	15 M/35 F	16 M/34 F	30 days	Intertrochanteric fracture	1, 2, 7, 8	Non-RCT	LOS, pain score, HHS, readmission rates, and mortality, DVT, delirium rate
Li et al., 2020	China	42	42	65.0 (5.3)	64.4 (5.2)	20 M/22 F	24 M/18 F	~	Hip fracture	1, 3, 4, 5, 8, 9	RCT	Pain score, HHS
Macfie et al., 2012	Danmark	117	115	82.5 (9.2)	82.7 (8.7)	28 M/89 F	24 M/91 F	6 months	Proximal femoral fractures	2, 3, 4, 8, 9	Retrospective cohort studies	LOS, complication rate, 1-year mortality, DVT
Pedersen et al., 2008	England	178	357	Male 76.9; female 83.9	Male 77.5; female 84.2	42 M/136 F	85 M/272 F	1 year	Hip fracture	2, 3, 4, 7, 8, 9	Retrospective cohort studies	Complication rate (delirium rate, pneumonia, and urinary tract infection), LOS, mortality, DVT
Pollmann et al., 2019	Norway	1,140	1,090	79.6 (0.3)	79.7 (0.3)	351 M/789 F	350 M/740 F	1 year	Proximal femoral fractures	2, 4, 7, 8, 9	Retrospective cohort studies	Mortality, readmission, LOS
Sura-amonrattana et al., 2021	Thailand	151	151	79.7 (7.85)	80.7 (7.51)	38 M/113 F	34 M/107 F	1 year	Hip fracture	1, 2, 4, 7, 8	Retrospective cohort studies	Incidence of medical complications, mortality, DVT
Liu et al., 2017	America	2,514	2,488	79.7 (11.7)	79.3 (11.9)	<u>_</u>	~	30 days	Hip fracture	1, 3, 4, 7, 8	Prospective cohort study	LOS, readmission rates, and complication rates
Note. DVT = deep vein thrombosis; ERAS = enhanced recovery after surgery; HHS = Harris Hip Score; LOS = length of stay; RCT = randomized controlled trial. *Enhanced recovery of surgery, not applicable; ERAS measures: (1) preoperative propaganda and education/psychological counseling, (2) optimizing anesthesia, (3) simplification of routine intestinal preparation before operation, (4) perioperative nutrition	nbosis; ERAS = y, not applicable	enhanced r	ecovery after s sures: (1) preo	surgery; HHS = Ha perative propagano	rris Hip Score; LOS la and education/p	 length of stay; R isychological counse 	CT = randomized cc ling, (2) optimizing a	introlled trial. nesthesia, (3) sim	plification of routine intes	tinal preparation t	before operation, (4) perioper	ative nutrition

276

www.journaloftraumanursing.com

Copyright © 2023 Society of Trauma Nurses.

Journal of Trauma Nursing 2023 Volume 30, Number 5

			Table 2. Qu	Table 2. Quality Assessment of Included Studies	of Included Studie	s			
		Selectio	tion		Comparability		Outcome		
Study Source	Representativeness of the Exposed Cohort	Selection of the Nonexposed Cohort	Ascertainment of Exposure	Demonstration That Outcome of Interest was not Present at Start of Study	Comparability of Cohorts on the Basis of the Design or Analysis	Assessment of Outcome	Was Follow-up Long Enough for Outcomes to Occur	Adequacy of Follow Up of Cohorts	Total Score
Gomez et al., 2019	-	1	-	-	2	-	-	-	6
Haugan et al., 2017	-	1	-	-	2	0	-	-	8
Kang et al., 2019	-	1	~	-	2	0	+	-	8
Li et al., 2020	t	1	~	-	2	0	0	-	7
Macfie et al., 2012	-	1	~	-	2	0	1	-	8
Pedersen et al., 2008	-	-		-	-	-	-	-	8
Pollmann et al., 2019	-	1	-	-	2	0	1	-	8
Sura-amonrattana et al., 2021	-	-	~	-	, -	0	-	~	7
Liu et al. 2017	-	-		-		-	0	-	7

2019; Macfie et al., 2012; Pedersen et al., 2008; Sura-Amonrattana et al., 2021) (see Supplemental Digital Content Figure 4c, available at: http://links.lww. com/JTN/A116). Meta-analysis showed no significant difference in respiratory tract infection rate across all five studies (RR = 0.76; 95% CI [0.50, 1.14]; p = .19) with low heterogeneity (p = .62, $I^2 = 0\%$).

DVT Rate

There were four studies (Gomez et al., 2019; Kang et al., 2019; Li et al., 2020; Sura-Amonrattana et al., 2021) with available data on DVT rate (see Supplemental Digital Content Figure 4d, available at: http://links. lww.com/JTN/A116). A fixed-effects model was applied, as the heterogeneity was not significant (p = .23, $I^2 = 31\%$). A significant reduction in DVT rate was not found in the ERAS patients compared with the control group (RR = 0.41; 95% CI [0.12, 1.40]; p = .16).

Delirium Rate

There were three studies (Gomez et al., 2019; Kang et al., 2019; Pedersen et al., 2008) with available data on delirium rate (see Supplemental Digital Content Figure 4e, available at: http://links.lww.com/JTN/ A116). A random-effects model was applied as the heterogeneity was moderate ($I^2 = 65\%$). No significant reduction in the delirium rate was found in the ERAS patients compared with the conventional nursing group (RR = 0.61; 95% CI [0.16, 2.37]; p = .47).

Publication Bias

The funnel plot and Egger's test were used to examine for publication bias. Egger's test showed no publication bias in LOS, 1-year mortality, readmissions, urinary tract infections, or respiratory tract infections (p = .26, .77, .87, .98, .60; see Supplemental Digital Content Figure 5, available at: http://links.lww.com/JTN/A117). Egger's test showed there was publication bias in the DVT rate (p = .001).

DISCUSSION

Hip fractures, a common osteoporotic injury in the elderly, cause pain and mobility issues, leading to long-term bed rest and a heightened risk of complications, sometimes life-threatening (de Bot et al., 2020). Early mobilization can enhance patients' quality of life and lower complications and mortality. ERAS, a multidisciplinary approach, aims to minimize perioperative trauma and stress, thus improving postoperative recovery and safety (Kehlet, 1997). It was introduced in China in 2007 by professor Li Jieshou of Nanjing Military Region General Hospital. Despite its widespread use in orthopedics (Ping et al., 2021; Yin et al., 2020), ERAS's efficacy in hip fracture prognosis is debated. Nurses are

Copyright © 2023 Society of Trauma Nurses.

		An eres			Conventio			Marrie C	Mean Difference	Mean Diffe	
Study or Subgroup		Aean		Total	Mean	SD		Weight	IV. Random, 95% CI	IV. Random,	BOJE CI
Gomez 2019	4		19.36	27	77.85	44.8	27	0.2%		-	
Haugan 2017		6.1	0.000	1032	9.5	8.2	788			-	
Kang 2019		5.82	0.64	50	8.21	0.83	50	17.4%	1. Constraint of the second s second second sec		
Liu 2017		3.2	1.56	2514	3.6	1.48	2488	17,7%		0000	
Macfie 2012		10	6.67	117	11.5	5.93	125	11.1%	-1.50 [-3.09, 0.09]		
Pederson 2008		9.7	9.2	178	15.8	18	357	7.9%	-6.10 [-8.40, -3.80]	100 C	
Pollmann 2019		5.2	2.44	1072	5.3	2.22	1054	17.6%	-0.10 [-0.30, 0.10]		
Sura-amonrattana 20	021	11	6.67	151	13	6.11	151	11.9%	-2.00 [-3.44, -0.56]		
Transfer int										· · · · · ·	
Total (95% CI)			i	5141			5040	100.0%	-2.00 [-2.87, -1.14]		- Q - Q
Heterogeneity: Tau*					< 0.0000 ⁻¹), P = 98	90			10 5 0	5 10
Test for overall effect	CZ=4.5	3 (P =	0.0000	0						Favours [ERAS] Fa	avours (control)
					1	Meta-	analy	vsis of	LOS across stu	dies	
						1014	and.	, 515 01	100 401000 514		
	EF	RAS		Conve	ntional n	ursing		N	lean Difference	Mean Differ	ence
udy or Subgroup	Mean	sn	Total	Mean	SD	Tot	a We	eight IV	, Random, 95% Cl	IV, Random, 9	15% CI
CALINO AN ON THE			22.5				10.00		the second s	IV, Nahuvin, a	10/11/07
ng 2019 9	90.51	6.51	50	90.32	6.82	5	0 49	9.9%	0.19 [-2.42, 2.80]	T	
2020	26.6	6.3	42	18.4	5.6	4	2 50	0.1%	8.20 [5.65, 10.75]		
200000	2.7657.575	12,426	11.55			÷	20120	1.1.1.1			
유지, 아이들은 이 것 같은 것을 줄을 수 없다.			19282			2	1.23	2485-6	1923 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 - 1926 -		22
tal (95% CI)			92			9	2 10	0.0%	4.20 [-3.65, 12.05]		22
terogeneity: Tau ² = 3	0.35 C	h#=1	8 49 6	f=1/P	< 0.0001	1 12 = 94	104			+ + +	- 1
10110- 5 11110-510-10110-1010-1010-			1000 D. C. M. C. M. C.	a - 1 V	- 0.0001	1,1 - 00				-50 -25 0	25 5
st for overall effect Z	= 1.05 (P=0	29)							Favours [ERAS] Fav	Inners Icontroll
				N	Meta-a	1alvsi	s of]	HHS 1	between studies	i eroure [ere is] i a	conce from oil
						5					
		ERAS	25	Con	ventional	nursing			Mean Difference	Mean Differe	BCO
	1000						1.000		The second second second second		101 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Study or Subgroup	Mean	5) Tota	Me Me	an s	D To	stal V	Veight	IV, Fixed, 95% Cl	IV, Fixed, 95	% CI.
Kang 2019	3.3	1.1.	3 4	2 -2	1.3 1.1	4	42	61.8%	-0.90 [-1.39, -0.41]	-8-	
Kang 2018	- 3.2									the second se	
				0 .1		52	50	38 2%	-1 04 L1 66 -0 421		
		1.6		0 -3	1.8 1.5	52	50	38.2%	-1.04 [-1.66, -0.42]	-	
LI 2020			3 5	84 - 58 		52					
				84 - 58 		52			-1.04 [-1.66, -0.42] -0.95 [-1.34, -0.57]	•	
Li 2020 Total (95% CI)	-4.84	1.6	3 5 9	2	1.8 1.5	52					
Li 2020 Total (95% Cl) Heterogeneity: Chi ² =	-4.84 0.12, d	1.6: f=1(9 5 9 P = 0.7	2 3); P= 0	1.8 1.5	52				+ + -2 -1 0	+ 1
Li 2020 Total (95% Cl) Heterogeneity: Chi ² =	-4.84 0.12, d	1.6: f=1(9 5 9 P = 0.7	2 3); P= 0	1.8 1.5	52					i 2
LI 2020	-4.84 0.12, d	1.6: f=1(3 5 9 P=0.7 0.000	2 3); P= (01)	1.8 1.5 196		92 1	00.0%	-0.95 [-1.34, -0.57] _	-2 -1 0 Favours [ERAS] Fav	1 2 rours [control]
Li 2020 Total (95% Cl) Heterogeneity: Chi ² =	-4.84 0.12, d	1.6: f=1(3 5 9 P=0.7 0.000	2 3); P= (01)	1.8 1.5 196		92 1	00.0%	-0.95 [-1.34, -0.57] _		1 2 rours [control]
Li 2020 Total (95% Cl) Heterogeneity: Chi ² =	-4.84 0.12, d	1.6: f=1(3 5 9 P=0.7 0.000	2 3); P= (01)	1.8 1.5 196		92 1	00.0%			1 2 rours (control)
Li 2020 Total (95% Cl) Heterogeneity: Chi ² =	-4.84 0.12, d	1.6: f=1(0(P <	3 5 9 9 = 0.7 0.000	2 3); P=0 01) Meta-	1.8 1.9 9% analysi	s of p	92 1	score t	••••••••••••••••••••••••••••••••••••••	Favours [ERAS] Fav	1 2 rours (control)
Li 2020 Total (95% CI) Heterogenelty: Chi ^e = Test for overall effect	-4.84 0.12, d Z = 4.9	1.6: f=1(0(P <	3 5 9 P=0.7 0.000] S	2 3); I ² = 0 01) Meta-	1.8 1.9 9% analysi	s of p	92 1 ain s	score t	-0.95 [-1.34, -0.57]	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% CI) Heterogeneity: Chi ^e = Test for overall effect	-4.84 0.12, d Z = 4.9	1.6: f=1(0(P <	3 5 9 9 = 0.7 0.000	2 3); I ² = 0 01) Meta-	1.8 1.9 9% analysi	s of p	92 1 ain s	score t	••••••••••••••••••••••••••••••••••••••	Favours [ERAS] Fav	1 2 rours (control)
Li 2020 Total (95% CI) Heterogeneity: Chi ^e = Test for overall effect	-4.84 0.12, d Z = 4.9	1.6: f=1(0(P <	3 5 9 P=0.7 0.000] S	2 3); I ² = 0 01) Meta-	1.8 1.9 9% analysi	s of p	92 1 ain s	score t	-0.95 [-1.34, -0.57]	Favours [ERAS] Fav	i 2 rours (control)
LI 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Study or Subproup	-4.84 0.12, d Z = 4.9	1.6: f = 1 (0 (P < ERA conts 6	3 5 9 P=0.7 0.000 1 S Total	2 3); P = 0 01) Meta- Eve	1.8 1.5 9% analysi ntional num	s of p rsing Total	92 1 ain s Weigt	800.0% score t Ra tt M-H.1 % 1.0	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	t 2 rours (control)
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect <u>Study or Subgroup</u> Gomez 2019 Haugan 2017	-4.84 0.12, d Z = 4.9	1.6: f = 1 (0 (P < ERA 6 259	3 5 9 9 = 0.7 0.000 1 5 <u>Total</u> 27 1032	2 3); P = 0 01) Meta- Conver	8.8 1.9 1% analysi ntional nu 15 5 213	s of p rsing <u>Total</u> 27 788	92 1 ain s <u>Weigt</u> 42.19	800.0% score t Ra <u>R M-H, 1</u> % 1.0 % 0.9	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect <u>Study or Subgroup</u> Gomez 2019 Haugan 2017 Pederson 2008	-4.84 0.12, d Z = 4.9	1.6: f = 1 (0 (P < ERA 6 259 41	3 5 9 9 = 0.7 0.000 1 5 <u>Total</u> 27 1032 178	2 3); P = 0 01) Meta- Conver	8.8 1.9 analysi ntional nu nts 6 213 104	s of p rsing Total 27 788 357	92 1 ain s 1.01 42.11 12.13	800.0% score t Ra tt M-H.1 % 1.0 % 0.9 % 0.7	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect <u>Study or Subproup</u> Gomez 2019 Haugan 2017 Pederson 2009 Pollmann 2019	-4.84 0.12, d Z = 4.9 Es	1.6: f = 1 (0 (P < ERA 6 259 41 260	3 5 9(P = 0.7 0.000] S <u>Total</u> 27 1032 178 1090	2 3); P = 0 01) Meta- Conver	8.8 1.9 analysi itional nu 5 213 104 249	s of p Total 27 788 357 1140	92 1 ain s 1.01 42.11 12.13 42.41	800.0% score t Ra M. M.H.I % 1.0 % 0.9 % 0.7 % 1.0	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours (control)
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect <u>Study or Subgroup</u> Gomez 2019 Haugan 2017 Pederson 2008	-4.84 0.12, d Z = 4.9 Es	1.6: f = 1 (0 (P < ERA 6 259 41	3 5 9 9 = 0.7 0.000 1 5 <u>Total</u> 27 1032 178	2 3); P = 0 01) Meta- Conver	8.8 1.9 analysi ntional nu nts 6 213 104	s of p rsing Total 27 788 357	92 1 ain s 1.01 42.11 12.13	800.0% score t Ra M. M.H.I % 1.0 % 0.9 % 0.7 % 1.0	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours (control)
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202	-4.84 0.12, d Z = 4.9 Es	1.6: f = 1 (0 (P < ERA 6 259 41 260	3 5 9(P=0.7 0.0000 1 5 1032 178 1090 151	2 3); P = 0 01) Meta- Conver	8.8 1.9 analysi itional nu 5 213 104 249	s of p Total 27 788 357 1140 151	92 1 ain s 1.01 42.11 12.11 42.41 2.41	Rin Rin M.H.I % 1.0 % 0.9 % 0.7 % 1.0 % 1.4	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl)	-4.84 0.12, d Z = 4.9 Es	1.6: f=1(0(P < ERA 6 259 41 260 20	3 5 9(P = 0.7 0.000] S <u>Total</u> 27 1032 178 1090	2 3); I [#] = (01) Meta- Conver Eve	1.8 1.9 analysi ntional num 6 213 104 249 14	s of p Total 27 788 357 1140	92 1 ain s 1.01 42.11 12.11 42.41 2.41	Rin Rin M.H.I % 1.0 % 0.9 % 0.7 % 1.0 % 1.4	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events	-4.84 0.12, d Z = 4.9 Ex	1.6: f=1(0(P < ERA 6 259 41 260 20 586	3 5 9 P = 0.7 0.000 3 <u>Total</u> 27 1032 179 1090 151 2478	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi ntional nu nts 6 213 104 249 14 586	s of p Total 27 788 357 1140 151	92 1 ain s 1.01 42.11 12.11 42.41 2.41	Rin Rin M.H.I % 1.0 % 0.9 % 0.7 % 1.0 % 1.4	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	i 2 rours [control]
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < ERA 259 41 260 20 5866 = 4 (P	3 5 9 9 P = 0.7 0.000 1 S 1032 178 1090 151 2478 = 0.24	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi ntional nu nts 6 213 104 249 14 586	s of p Total 27 788 357 1140 151	92 1 ain s 1.01 42.11 12.11 42.41 2.41	Rin Rin M.H.I % 1.0 % 0.9 % 0.7 % 1.0 % 1.4	-0.95 [-1.34, -0.57] 	Favours [ERAS] Fav	
Li 2020 Total (95% Cl) Heterogeneity: Ch? = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < ERA 259 41 260 20 5866 = 4 (P	3 5 9 9 P = 0.7 0.000 1 S 1032 178 1090 151 2478 = 0.24	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi ntional nu nts 6 213 104 249 14 586	s of p Total 27 788 357 1140 151	92 1 ain s 1.01 42.11 12.11 42.41 2.41	Rin Rin M.H.I % 1.0 % 0.9 % 0.7 % 1.0 % 1.4	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] 3 [0.79, 1.08] 9 [0.58, 1.08] 9 [0.94, 1.27] 3 [0.75, 2.72] 9 [0.90, 1.10]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < ERA 259 41 260 20 5866 = 4 (P	3 5 99 P = 0.7 0.0000] 3 5 7054 1032 178 1090 151 151 2478 = 0.24 0.91)	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi analysi analysi analysi b c c c c c c c c c c c c c	s of p Total 27 788 357 1140 151 2463	92 1 ain s 1.09 42.19 12.11 42.49 2.49	800.0% Score b Ra M M-H.1 % 1.0 % 0.9 % 1.0 % 1.4 % 0.9	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] + 9 [0.59, 1.08] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10]	Risk Ratio M-H, Fixed, 95% Cl	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < ERA 259 41 260 20 5866 = 4 (P	3 5 99 P = 0.7 0.0000] 3 5 7054 1032 178 1090 151 151 2478 = 0.24 0.91)	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi analysi analysi analysi b c c c c c c c c c c c c c	s of p Total 27 788 357 1140 151 2463	92 1 ain s 1.09 42.19 12.11 42.49 2.49	800.0% Score b Ra M M-H.1 % 1.0 % 0.9 % 1.0 % 1.4 % 0.9	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] + 9 [0.59, 1.08] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10]	Risk Ratio M-H, Fixed, 95% Cl	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < ERA 259 41 260 20 5866 = 4 (P	3 5 99 P = 0.7 0.0000] 3 5 7054 1032 178 1090 151 151 2478 = 0.24 0.91)	2 3); P= 0 01) Meta- Conver Eve	1.8 1.9 analysi analysi analysi analysi b c c c c c c c c c c c c c	s of p Total 27 788 357 1140 151 2463	92 1 ain s 1.09 42.19 12.11 42.49 2.49	800.0% Score b Ra M M-H.1 % 1.0 % 0.9 % 1.0 % 1.4 % 0.9	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] 3 [0.79, 1.08] 9 [0.58, 1.08] 9 [0.94, 1.27] 3 [0.75, 2.72] 9 [0.90, 1.10]	Risk Ratio M-H, Fixed, 95% Cl	
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% CI) Total events Heterogeneity: Chi ² = 1	-4.84 = 0.12, d Z = 4.9 	1.6: f=1(0(P < 259 41 260 20 586 586 =4(P = (3 5 9 9 P = 0.7 0.0000] 3 5 7052 1032 178 1090 151 2478 = 0.24 0.91) Met	2 3); P= 0 01) Meta- <u>Eve</u> ; P= 27 ¹ a-ana	1.8 1.9 analysi analysi analysi 104 249 14 586 % lysis o	s of p <u>Total</u> 27 788 357 1140 151 2463 f one-	92 1 ain s 1.09 42.19 12.11 42.49 2.49	Ra Ra M. M.H. 1 % 1.0 % 0.9 % 1.4 % 1.4 % 0.9 % 0.9 % 0.9	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] ← 3 [0.79, 1.08] ← 9 [0.94, 1.27] 3 [0.75, 2.72] ← 9 [0.90, 1.10]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0 (P < ERA 6 259 41 260 20 586 6 586 (P = (ERA	3 5 9 9 P = 0.7 0.0000 1 1 1032 178 1090 151 2478 = 0.24 0.91) Met	2 3); P = 0 01) Meta- <u>Eve</u> ; P = 27' a-ana	1.8 1.9 analysi ttional num 6 213 104 249 14 586 % lysis o ntional num	s of p <u>Total</u> 27 788 357 1140 151 2463 f one- rsing	92 1 ain s 1.09 42.19 12.19 42.49 2.49 100.09	800.0% score b 80 80 80 80 80 80 80 80 80 80 80 80 80	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.09] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] - tality across stu isk Ratio	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2009 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 5 Test for overall effect 2 Study or Subgroup	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA rents 5259 41 260 20 586 =4(P) (P = (ERA rents	3 5 9 9 P = 0.7 0.0000 1 1 27 1032 178 1090 151 151 2478 2478 2478 2478 2478 2478 2478 5 5 Total	2 3); P = 0 01) Meta- <u>Eve</u> ; P = 27' a-ana	1.8 1.1 1% analysi tional num 104 249 14 586 % lysis o ntional num nts	s of p sing Total 27 788 357 1140 151 2463 f one- rsing Total	92 1 ain s 107 4219 1219 4249 249 100.0°	800.0% score b 80 80 80 80 80 80 80 80 80 80 80 80 80	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.08] + 9 [0.59, 1.08] + 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% Cl	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI	
Li 2020 Total (95% Cl) Heterogeneity: Ch ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Ch ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA conts 59 41 260 20 586 =4(P=((P=(ERA vents 7	3 5 9 9 P = 0.7 0.0000] 3 5 <u>Total</u> 2478 1090 151 2478 = 0.24(9.91) Met 5 <u>Total</u> 20	2 3); P = 0 01) Meta Conver Eve 2, P = 27' a-ana Conver Eve	1.8 1.1 1% analysi ntional num 104 249 14 586 % lysis o ntional num 14 586 %	s of p <u>Total</u> 27 788 357 1140 151 2463 f one- rsing	92 1 ain s 107 4219 1211 42.49 2.49 100.0° -yea <u>Weig</u>	800.0% score b 100.0% 100% 0.9 % 0.7 % 1.0 % 0.9 r mor R 100 % 0.9	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.08] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% Cl 70 [0.33, 1.49] +	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2009 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA conts 59 41 260 20 586 =4(P=((P=(ERA vents 7	3 5 9 9 P = 0.7 0.0000 1 1 27 1032 178 1090 151 151 2478 2478 2478 2478 2478 2478 2478 5 5 Total	2 3); P = 0 01) Meta Conver Eve 2, P = 27' a-ana Conver Eve	1.8 1.1 1% analysi tional num 104 249 14 586 % lysis o ntional num nts	s of p rsing 27 788 357 1140 151 2463 f one- rsing Total	92 1 ain s 107 4219 1219 4249 249 100.0°	800.0% score b 100.0% 100% 0.9 % 0.7 % 1.0 % 0.9 r mor R 100 % 0.9	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.08] + 9 [0.59, 1.08] + 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% Cl	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA conts 59 41 260 20 586 =4(P=((P=(ERA vents 7	3 5 9 9 P = 0.7 0.0000 1 1 27 1032 178 1032 178 1032 178 1090 151 2478 = 0.24(991) Met 5 <u>Total</u> 20	2 3); P = 0 01) Meta Conver Eve 2, P = 27' a-ana Conver Eve	1.8 1.1 1% analysi ntional num 104 249 14 586 % lysis o ntional num 14 586 %	s of p rsing 27 788 357 1140 151 2463 f one- rsing Total 18	92 1 ain s 107 4219 1211 42.49 100.0° -yea <u>Weig</u>	Recore b Rent M-H, 1 % 1.0 % 0.9 % 0.9 % 1.4 % 0.9 % 0.9 % 0.9 r mor Rent M-H, 1 % 0.3 % 0.1	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.08] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% Cl 70 [0.33, 1.49] +	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA 6 259 41 260 20 586 586 (P = (P = (FRA 406 0 0 0 0 0 0 0 0 0 0 0 0 0	3 5 9 9 P = 0.7 0.0000] s <u>Total</u> 27 1032 178 1090 151 2478 = 0.24(991) Met 5 <u>Total</u> 202(991) Met 5 <u>Total</u> 202(901)	2 3); P= 0 01) Meta- Eve Eve 2, P= 27 a-ana Conver Eve	1.8 1.1 1% analysi analysi 104 249 14 586 % lysis o antional nu 19 9 319 0	s of p <u>Total</u> 27 788 357 1140 151 2463 f one- rsing <u>Total</u> 18 788 50	92 1 ain s 1.00 42.19 12.19 12.19 2.49 100.0° -yea <u>Weig</u> 1.1 43.4	Recore to Recore to 10 M-H. 10 M-H.	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] * 3 [0.79, 1.08] * 9 [0.96, 1.08] * 9 [0.90, 1.10] fixed, 95% Cl fixed, 95% Cl 1 (0.33, 1.49] * 7 [0.87, 1.09] Not estimable	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 4 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Liu 2017	-4.84 0.12, d Z = 4.9 Ex 21 5.46, df Z = 0.11	1.6: f=1(0(P < ERA 6 259 41 260 20 586 9 40 6 20 586 (P = (P = (ERA 40 6 342	3 5 99 P=0.7 0.0000] s <u>Total</u> 27 1032 178 1090 151 2478 = 0.24 0.91) Met s <u>Total</u> 0.91) Met	2 3); P = 0 01) Meta- Eve Eve 2, P = 27 ¹ a-ana Conver Eve	1.8 1.1 1.8 1.1 1.8 1.9% 1.04 1	s of p <u>sing</u> 27 788 357 1140 151 2463 f one- rsing <u>Total</u> 18 788 50 2488	92 1 ain s 1.01 42.11 12.19 2.41 100.0 ⁰ -yea 1.1 43.4 36.1	800.0% Score b Ra 1. M-H.1 % 1.0 % 0.9 % 1.4 % 0.9 r mor R M-H.4 % 0.1 % 0.1 % 1.1	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.90, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] fixed, 95% Cl fixed, 95% Cl 10 [0.33, 1.49] + 97 [0.87, 1.09] Not estimable 13 [0.98, 1.31]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2018 Liu 2017 Pollmann 2019	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E	1.6: f=1(0 (P < ERA 6 259 41 260 20 586 586 (P = (ERA vents 7 406 0 342 133	3 5 9 9 P = 0.7 0.0000] 3 5 70tal 1090 151 2478 = 0.24 0.91) Met 5 5 70tal 202 50 2514 1140	2 3); P = 0 01) Meta- Eve Eve 2, P = 27 a-ana Conver Eve	1.8 1.1 1% analysi analysi analysi 1004 249 14 586 % lysis o ntional nu ents 9 319 0 299 140	s of p rsing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090	92 1 ain s 1.01 42.11 12.19 42.41 2.41 100.00 -yea 100.00 -yea 1.1 43.4 36.1 17.2	Ra Ra M MH S 10 S 0.9 S 1.0 S 1.4 S 0.9 T mor R M MH S 0.9 T mor R M MH S 0.1 S 0.	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] + 9 [0.59, 1.08] + 9 [0.59, 1.08] + 9 [0.90, 1.10] + sk Ratio Fixed, 95% CI fixed, 95% CI 70 [0.33, 1.49] + 97 [0.87, 1.09] + Not estimable 13 [0.96, 1.31] 91 [0.73, 1.13]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 4 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Liu 2017	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E	1.6: f=1(0(P < ERA 6 259 41 260 20 586 9 40 6 20 586 (P = (P = (ERA 40 6 342	3 5 99 P=0.7 0.0000] s <u>Total</u> 27 1032 178 1090 151 2478 = 0.24 0.91) Met s <u>Total</u> 0.91) Met	2 3); P = 0 01) Meta- Eve Eve 2, P = 27 a-ana Conver Eve	1.8 1.1 1.8 1.1 1.8 1.9% 1.04 1	s of p <u>sing</u> 27 788 357 1140 151 2463 f one- rsing <u>Total</u> 18 788 50 2488	92 1 ain s 1.01 42.11 12.19 2.41 100.0 ⁰ -yea 1.1 43.4 36.1	Ra Ra M MH S 10 S 0.9 S 1.0 S 1.4 S 0.9 T mor R M MH S 0.9 T mor R M MH S 0.1 S 0.	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% Cl 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.90, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] fixed, 95% Cl fixed, 95% Cl 10 [0.33, 1.49] + 97 [0.87, 1.09] Not estimable 13 [0.98, 1.31]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Ch ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Haugan 2017 Kang 2019 Sura-amonrattana 202 Sura-amonrattana 202	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E	1.6: f=1(0 (P < ERA 6 259 41 260 20 586 586 (P = (ERA vents 7 406 0 342 133	3 5 9 9 P = 0.7 0.0000] 3 5 <u>Total</u> 2478 20 1032 179 1090 151 2478 8 0.2478 Net 5 <u>Total</u> 20 1032 504 1140 151	2 3); P = 0 01) Meta- Eve Eve 2, P = 27 a-ana Conver Eve	1.8 1.1 1% analysi analysi analysi 1004 249 14 586 % lysis o ntional nu ents 9 319 0 299 140	s of p sing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090 151	92 1 ain s 1.01 42.19 12.19 12.19 12.19 12.19 12.19 12.19 2.49 100.09 -yea <u>Weigt</u> 1.1 43.4 36.11 17.2 2.2	Recore b Re <u>IN M-H.1</u> % 1.0 % 0.9 % 1.0 % 1.4 % 0.9 % 1.7 % 0.1 % 1.7 % 0.1	0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] 9 [0.58, 1.08] 9 [0.58, 1.08] 9 [0.90, 1.27] 3 [0.75, 2.72] 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% CI 70 [0.33, 1.49] 97 [0.87, 1.09] Not estimable 13 [0.96, 1.31] 91 [0.73, 1.13] 11 [0.61, 2.02]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2018 Liu 2017 Pollmann 2019	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E	1.6: f=1(0 (P < ERA 6 259 41 260 20 586 586 (P = (ERA vents 7 406 0 342 133	3 5 9 9 P = 0.7 0.0000] 3 5 70tal 1090 151 2478 = 0.24 0.91) Met 5 5 70tal 202 50 2514 1140	2 3); P = 0 01) Meta- Eve Eve 2, P = 27 a-ana Conver Eve	1.8 1.1 1% analysi analysi analysi 1004 249 14 586 % lysis o ntional nu ents 9 319 0 299 140	s of p rsing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090	92 1 ain s 1.01 42.19 12.19 12.19 12.19 12.19 12.19 12.19 2.49 100.09 -yea <u>Weigt</u> 1.1 43.4 36.11 17.2 2.2	Recore b Re <u>IN M-H.1</u> % 1.0 % 0.9 % 1.0 % 1.4 % 0.9 % 1.7 % 0.1 % 1.7 % 0.1	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] + 9 [0.59, 1.08] + 9 [0.59, 1.08] + 9 [0.90, 1.10] + sk Ratio Fixed, 95% CI fixed, 95% CI 70 [0.33, 1.49] + 97 [0.87, 1.09] + Not estimable 13 [0.96, 1.31] 91 [0.73, 1.13]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Haugan 2017 Kang 2019 Bura-amonrattana 202 Sura-amonrattana 202	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E	1.6: f=1(0 (P < ERA 6 259 41 260 20 586 586 (P = (ERA vents 7 406 0 342 133	3 5 9 9 P = 0.7 0.0000] 3 5 <u>Total</u> 2478 20 1032 179 1090 151 2478 8 0.2478 Net 5 <u>Total</u> 20 1032 504 1140 151	2 3); P= 0 01) Meta- Conver Eve 2, P = 27' a-ana Conver	1.8 1.1 1% analysi analysi analysi 1004 249 14 586 % lysis o ntional nu ents 9 319 0 299 140	s of p sing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090 151	92 1 ain s 1.01 42.19 12.19 12.19 12.19 12.19 12.19 12.19 2.49 100.09 -yea <u>Weigt</u> 1.1 43.4 36.11 17.2 2.2	Recore b Re <u>IN M-H.1</u> % 1.0 % 0.9 % 1.0 % 1.4 % 0.9 % 1.7 % 0.1 % 1.7 % 0.1	0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] 9 [0.58, 1.08] 9 [0.58, 1.08] 9 [0.90, 1.27] 3 [0.75, 2.72] 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% CI 70 [0.33, 1.49] 97 [0.87, 1.09] Not estimable 13 [0.96, 1.31] 91 [0.73, 1.13] 11 [0.61, 2.02]	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	
Li 2020 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Polimann 2019 Sura-amonrattana 202 Total (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Liu 2017 Polimann 2019 Sura-amonrattana 202 Total (95% CI) Total events	-4.84 0.12, d Z = 4.9 21 5.46, df Z = 0.11 E 21	1.6: f=1(0(P < ERA 6 259 41 260 20 586 586 6 269 20 586 6 20 586 6 20 586 6 342 133 20 908	3 5 99 P=0.7 0.0000] s <u>Total</u> 27 1032 178 1090 151 2478 = 0.24() 991) Met 5 <u>Total</u> 0.91) Met 151 2514 1140 151 4907	2 3); P= 0 01) Meta- Eve 5; P= 27 a-ana Conver	1.8 1.1 1.8 1.1 1.8 1.1 1.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	s of p sing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090 151	92 1 ain s 1.01 42.19 12.19 12.19 12.19 12.19 12.19 12.19 2.49 100.09 -yea <u>Weigt</u> 1.1 43.4 36.11 17.2 2.2	Recore b Re <u>IN M-H.1</u> % 1.0 % 0.9 % 1.0 % 1.4 % 0.9 % 1.7 % 0.1 % 1.7 % 0.1	-0.95 [-1.34, -0.57] between studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] + 3 [0.79, 1.08] 9 [0.58, 1.08] + 9 [0.94, 1.27] 3 [0.75, 2.72] - 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% CI 70 [0.33, 1.49] + 97 [0.87, 1.09] Not estimable 13 [0.98, 1.31] 11 [0.61, 2.02] - 12 [0.94, 1.11]	Favours [ERAS] Favours [ERAS] Favours [ERAS] Favours [ERAS] Favours [ERAS] Favours [Contemporation of the second o	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Li 2020 Total (95% Cl) Heterogeneity: Ch ² = Test for overall effect Study or Subgroup Gomez 2019 Haugan 2017 Pederson 2008 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl) Total events Heterogeneity: Ch ² = 5 Test for overall effect 2 Study or Subgroup Gomez 2019 Haugan 2017 Kang 2019 Liu 2017 Pollmann 2019 Sura-amonrattana 202 Total (95% Cl)	-4.84 0.12, d Z = 4.9 E 21 5.46, df Z = 0.11 E 21	1.6: f=1(0(P < ERAA 6 259 41 260 200 5866 =4 (P (P=(ERAA 0 342 133 20 908 =4 (P	3 5 9 9 P = 0.7 0.0000] 3 5 7051 1090 151 2478 = 0.24 0.91) Met 5 7051 202 50 2514 1140 151 202 2514 1140 151 202 2514 1140 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 2514 202 202 202 202 202 202 202 202 202 20	2 3); P= 0 01) Meta- Eve 5; P= 27 a-ana Conver	1.8 1.1 1.8 1.1 1.8 1.1 1.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	s of p sing Total 27 788 357 1140 151 2463 f one- rsing Total 18 788 50 2488 1090 151	92 1 ain s 1.01 42.19 12.19 12.19 12.19 12.19 12.19 12.19 2.49 100.09 -yea <u>Weigt</u> 1.1 43.4 36.11 17.2 2.2	Recore b Re <u>IN M-H.1</u> % 1.0 % 0.9 % 1.0 % 1.4 % 0.9 % 1.7 % 0.1 % 1.7 % 0.1	-0.95 [-1.34, -0.57] Detween studies sk Ratio Fixed, 95% CI 0 [0.37, 2.71] * 3 [0.79, 1.08] * 9 [0.96, 1.27] 3 [0.75, 2.72] 9 [0.90, 1.10] tality across stu isk Ratio Fixed, 95% CI 70 [0.33, 1.49] * 97 [0.87, 1.09] Not estimable 13 [0.96, 1.31] 21 [0.73, 1.13] 11 [0.61, 2.02] 12 [0.94, 1.11] 	Favours [ERAS] Fav Risk Ratio M-H, Fixed, 95% CI 0.85 1.1 1 Favours [ERAS] Favours [co dies Risk Ratio	- - 1.5

Meta-analysis of readmission rate across studies

Figure 3. Forest plots for primary outcomes. (A) Meta-analysis of length of stay across studies. (B) Meta-analysis of Harris Hip Score between studies. (C) Meta-analysis of pain score between studies. (D) Meta-analysis of 1-year mortality across studies. (E) Meta-analysis of readmission rate across studies. ERAS = enhanced recovery after surgery.

278 www.journaloftraumanursing.com

Copyright © 2023 Society of Trauma Nurses.

key in identifying frail patients and coordinating preoperative patient education, functional training, and nutritional support (Eriksson et al., 2012).

Moreover, nurses are at the forefront of providing postoperative care, such as pain management, early mobilization, and fluid restriction, essential components of the ERAS pathway. Future research should focus on the specific nursing interventions that can be optimized within the ERAS framework to improve the care and outcomes of hip fracture patients, particularly those with varying levels of frailty.

In the present meta-analysis, nine studies were reviewed, in which 10,359 older patients with hip fractures were included to determine the effect of ERAS on prognosis (1-year mortality, readmission rate, HHS, pain score, LOS, and incidence of complications). The baseline frailty status of older patients is an important factor to consider in our study, as frailty is known to impact the recovery of hip fracture patients significantly. Although the included studies in our meta-analysis did not uniformly report the frailty status of their participants, it is essential to acknowledge that frailty could have contributed to the observed differences in outcomes between the ERAS and control groups. Frailty reflects biological aging and can influence various aspects of the patient's recovery, including the length of hospital stay, overall complication rate, and functional outcomes such as the HHS. In future studies, it would be beneficial to assess the frailty status of patients at baseline and stratify the results accordingly, allowing for a more comprehensive understanding of the effects of ERAS programs on different subgroups of older patients and facilitating personalized care for hip fracture patients with varying frailty levels.

The results of this study revealed that ERAS had potential benefits for patients with hip fractures, such as reducing the overall complication rate, shortening LOS, and relieving postoperative pain. However, there was no significant difference in HHS between the ERAS and control groups. The severity of hip fractures may affect the postoperative recovery of patients. Most of the included studies did not assess and compare the hip fractures severity, which may lead to the bias of research results to a certain extent. Significant differences were found in the overall complication rate among four of the nine included studies. Still, the heterogeneity among studies was high, possibly related to overlapping CIs of study results.

However, there was no significant difference in urinary tract infection rate, respiratory tract infection rate, incidence of delirium, and DVT rate. This study's results differed from those of previous studies (Liu et al., 2021), which may be because this review incorporated more studies than previous studies, and the types of included studies consisted of not only cohort studies but

Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Trauma Nurses.

also interventional studies. In ERAS, pain management is one of the most important constituents.

This meta-analysis showed a remarkable reduction in pain scores between the two groups, consistent with the study by Kang et al. (2019). To the best of our knowledge, traditional pain management involves administering proper measures when the patient complains of unbearable pain. As for managing postoperative pain, ERAS was to administer Cyclooxygenase-2 inhibitor analgesia before the complete extinction of anesthesia, emphasizing advanced and multi-mode analgesia. This may reduce the influence of adverse factors on the body's stress response, alleviate pain, and promote rapid recovery.

Postoperatively, ERAS focuses on postoperative analgesia, early feeding, early activity, and fluid restriction. A significant reduction of LOS between the two groups was discovered in our study, which was consistent with the study by Gomez et al. (2019). Postoperative analgesia can effectively improve patients' mood, help them to ambulate early, eat early and thus promote the recovery of various organ functions in the body, thereby reducing LOS. In addition, limiting the amount of fluid can reduce gastrointestinal mucosa edema, promote the recovery of gastrointestinal function and thus reduce LOS. However, there was no significant difference in readmission rate and 1-year mortality between the two groups, which may be related to the short follow-up time of each study and regional differences.

According to our results, ERAS has worked well in perioperative patients with hip fractures for the following reasons: preoperative patient education, functional training, shortened water fasting, removal of unnecessary bowel preparation, and nutritional support. It can effectively reduce patients' anxiety and fear and reduce the incidence of surgical stress response and postoperative complications. Active preoperative functional exercise helps improve the patient's body function, increase body tolerance, and promote postoperative physical recovery (Jiang et al., 2021).

Shortening patients' water fasting and removing unnecessary bowel preparation can, to some extent, relieve the patient's psychological stress and reduce their discomfort. Eating carbohydrates 2 hr before surgery can effectively promote insulin secretion in the body, increase insulin sensitivity, improve the body's tolerance, and does not increase the risk of aspiration during anesthesia (Peng & Li, 2021). During surgery, ERAS strategies focus on temperature control, fluid input control, central venous pressure control, anesthesia selection, and drainage tube placement. Controlling central venous pressure can reduce the amount of intraoperative blood loss and control the patient's body temperature and fluid input, effectively reducing the risk of hemodynamic instability and ultimately reducing the incidence of postoperative complications (Kang et al., 2019). Anesthesia focuses on general anesthesia and epidural anesthesia, which can reduce the use of general anesthesia drugs and have a good anesthetic effect, thereby reducing the load of each organ in the body and promoting the recovery of each organ function in the patient's body. Postoperative stimulation of drainage tubes to patients may cause psychological and physiological discomfort to a certain extent. Without the placement of a gravity tube, patients can get out of bed as soon as possible and further reduce the incidence of complications (Proudfoot et al., 2017).

LIMITATIONS

The limitations of this study are as follows: First, the majority of older patients with hip fractures had risk factors for poor incisional healing, such as advanced age, smoking, underlying diseases (such as diabetes and hypertension), or a history of medication use. Failure to control for these baseline factors may lead to a mixing bias. Second, this study could not explore the interactions between subgroup factors due to the limitations of the data reported in the included studies. In other words, although most included studies adjusted for confounding variables, our study failed to eliminate the impact of individual confounding factors, which may have affected the consistency of results. Despite the aforementioned limitations, which might have affected the conclusions and implications derived from our meta-analysis, the findings of this study are of referential value to medical professionals and may serve as a foundation for the development of ERAS care strategies in the future.

CONCLUSION

Perioperative care based on ERAS has potential benefits for the prognosis of patients after hip fractures, such as reduced LOS, relief of postoperative pain, and lower incidence of postoperative complications. However, due to the limitations, the results must be cautiously generalized. In future research, well-designed studies with larger sample sizes and longer follow-ups can be conducted worldwide, especially in developing countries, to validate this study's findings further.

Orcid iDs

Ruiqi Zhu b https//orcid.org/0000-0001-9531-9732 Fengqiao Yang b https//orcid.org/0000-0002-8672-6413 Caiying Li https//orcid.org/0000-0002-8322-838X Hongxia Zhu https//orcid.org/0000-0002-9226-5959 Lu Lin https//orcid.org/0000-0002-2049-4605 Xin Zhao https//orcid.org/0000-0003-3377-6801

REFERENCES

- Alexiou, K. I., Roushias, A., Varitimidis, S. E., & Malizos, K. N. (2018). Quality of life and psychological consequences in elderly patients after a hip fracture: A review. *Clinical Interventions in Aging*, 13, 143–150. https://doi.org/10.2147/cia.S150067
- Anderson, K. L., Koval, K. J., & Spratt, K. F. (2009). Hip fracture outcome: Is there a "July effect"? *American Journal of Orthopedics* (*Belle Mead NJ*), 38(12), 606–611.
- Bai, J., Liang, Y., Zhang, P., Liang, X., He, J., Wang, J., & Wang, Y. (2020). Association between postoperative delirium and mortality in elderly patients undergoing hip fractures surgery: A metaanalysis. *Osteoporosis International*, *31*(2), 317–326. https://doi. org/10.1007/s00198-019-05172-7
- Balfour, A., Amery, J., Burch, J., & Smid-Nanninga, H. (2022). Enhanced recovery after surgery (ERAS®): Barriers and solutions for nurses. *Asia-Pacific Journal of Oncology Nursing*, 9(7), 100040. https://doi.org/10.1016/j.apjon.2022.02.002
- de Bot, R. T. A. L., Veldman, H. D., Witlox, A. M., van Rhijn, L. W., & Hiligsmann, M. (2020). Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk. *Osteoporosis International*, *31*(7), 1217–1229. https://doi.org/10.1007/s00198-019-05252-8
- Eriksson, M., Kelly-Pettersson, P., Stark, A., Ekman, A. K., & Sköldenberg, O. (2012). "Straight to bed" for hip-fracture patients: A prospective observational cohort study of two fast-track systems in 415 hips. *Injury*, 43(12), 2126–2131. https://doi.org/10.1016/j. injury.2012.05.017
- Gomez, M., Marc, C., Talha, A., Ruiz, N., Noublanche, S., Gillibert, A., Bergman, S., Rony, L., Maynard, V., & Hubert, L.; Western France Orthopedic Society (SOO). (2019). Fast track care for pertrochanteric hip fractures: How does it impact length of stay and complications? Orthopaedics & Traumatology, Surgery & Research, 105(5), 979–984. https://doi.org/10.1016/j. otsr.2019.04.017
- Haugan, K., Johnsen, L. G., Basso, T., & Foss, O. A. (2017). Mortality and readmission following hip fracture surgery: A retrospective study comparing conventional and fast-track care. *BMJ Open*, 7(8), e015574. https://doi.org/10.1136/bmjopen-2016-015574
- Husted, H., Otte, K. S., Kristensen, B. B., Orsnes, T., & Kehlet, H. (2010). Readmissions after fast-track hip and knee arthroplasty. *Archives of Orthopaedic and Trauma Surgery*, 130(9), 1185– 1191. https://doi.org/10.1007/s00402-010-1131-2
- Jiang, M., Liu, S., Deng, H., Liang, X., & Bo, Z. (2021). The efficacy and safety of fast track surgery (FTS) in patients after hip fracture surgery: A meta-analysis. *Journal of Orthopaedic Surgery and Research*, 16(1), 162. https://doi.org/10.1186/s13018-021-02277-w
- Kang, Y., Liu, J., Chen, H., Ding, W., Chen, J., Zhao, B., & Yin, X. (2019). Enhanced recovery after surgery (ERAS) in elective intertrochanteric fracture patients result in reduced length of hospital stay (LOS) without compromising functional outcome. *Journal* of Orthopaedic Surgery and Research, 14(1), 209. https://doi. org/10.1186/s13018-019-1238-2
- Kehlet, H. (1997). Multimodal approach to control postoperative pathophysiology and rehabilitation. *British Journal of Anaesthe*sia, 78(5), 606–617. https://doi.org/10.1093/bja/78.5.606
- Li, H., Liu, Y., Li, Q., Fan, J., Gan, L., & Wang, Y. (2020). Effects of a fast track surgery nursing program in perioperative care of older patients with a hip fracture. *European Geriatric Medicine*, 11(4), 519–525. https://doi.org/10.1007/s41999-020-00298-y
- Liu, S. Y., Li, C., & Zhang, P. X. (2021). Enhanced recovery after surgery for hip fractures: A systematic review and meta-analysis. *Perioperative Medicine (London, England)*, 10(1), 31. https:// doi.org/10.1186/s13741-021-00201-8
- Liu, V. X., Rosas, E., Hwang, J., Cain, E., Foss-Durant, A., Clopp, M., Huang, M., Lee, D. C., Mustille, A., Kipnis, P., & Parodi, S. (2017). Enhanced recovery after surgery program implementation in 2 surgical populations in an integrated health care delivery system. *JAMA Surgery*, *152*(7), e171032. https://doi.org/10.1001/ jamasurg.2017.1032

- Macfie, D., Zadeh, R. A., Andrews, M., Crowson, J., & Macfie, J. (2012). Perioperative multimodal optimisation in patients undergoing surgery for fractured neck of femur. *The Surgeon*, 10(2), 90–94. https://doi.org/10.1016/j.surge.2011.01.006
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. https://doi.org/10.1136/bmj.n71
- Pedersen, S. J., Borgbjerg, F. M., Schousboe, B., Pedersen, B. D., Jørgensen, H. L., Duus, B. R., & Lauritzen, J. B. (2008). A comprehensive hip fracture program reduces complication rates and mortality. *Journal of the American Geriatrics Society*, 56(10), 1831–1838. https://doi.org/10.1111/j.1532-5415.2008.01945.x
- Peng, N., & Li, J. (2021). Application effect of case management mode combined with ERAS in elderly patients with hip fracture. *Evidence-Based Complementary and Alternative Medicine*, 2021, 1175020. https://doi.org/10.1155/2021/1175020
- Ping, H., Ling, X., Xue, Y., & Dong, F. (2021). Effect of ERAS combined with comfortable nursing on quality of life and complications in femoral neck fractures of the aged people. *Evidence-Based Complementary and Alternative Medicine*, 2021, 8753076. https://doi.org/10.1155/2021/8753076

- Pollmann, C. T., Røtterud, J. H., Gjertsen, J. E., Dahl, F. A., Lenvik, O., & Årøen, A. (2019). Fast track hip fracture care and mortality an observational study of 2230 patients. *BMC Musculoskeletal Disorders*, 20(1), 248. https://doi.org/10.1186/s12891-019-2637-6
- Proudfoot, S., Bennett, B., Duff, S., & Palmer, J. (2017). Implementation and effects of enhanced recovery after surgery for hip and knee replacements and fractured neck of femur in New Zealand orthopaedic services. *The New Zealand Medical Journal*, 130(1455), 77–90.
- Stang, A. (2010). Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. *European Journal of Epidemiology*, 25(9), 603-605. http://doi.org/10.1007/s10654-010-9491-z
- Sura-Amonrattana, U., Tharmviboonsri, T., Unnanuntana, A., Tantigate, D., & Srinonprasert, V. (2021). Evaluation of the implementation of multidisciplinary fast-track program for acute geriatric hip fractures at a University Hospital in resource-limited settings. *BMC Geriatrics*, 21(1), 548. https://doi.org/10.1186/ s12877-021-02509-y
- Yin, M., Yan, Y., Fan, Z., Fang, N., Wan, H., Mo, W., & Wu, X. (2020). The efficacy of enhanced recovery after surgery (ERAS) for elderly patients with intertrochanteric fractures who received surgery: Study protocol for a randomized, blinded, controlled trial. *Journal of Orthopaedic Surgery and Research*, 15(1), 91. https:// doi.org/10.1186/s13018-020-01586-w

For more than 120 additional nursing continuing professional development activities related to trauma topics, go to NursingCenter.com/ce.

NursingCenter*

TEST INSTRUCTIONS

• Read the article. The test for this nursing continuing professional development (NCPD) activity is to be taken online at **www**.

NursingCenter.com/CE/JTN. Tests can no longer be mailed or faxed. • You'll need to create an account (it's free!) and log in to access My

Planner before taking online tests. Your planner will keep track of all your Lippincott Professional Development online NCPD activities for you.

• There's only one correct answer for each question. A passing score for this test is 7 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.

For questions, contact Lippincott Professional Development: 1-800-787-8985.

• Registration deadline is September 5, 2025.

PROVIDER ACCREDITATION

Lippincott Professional Development will award 2.5 contact hours for this nursing continuing professional development activity.

NURSING Continuing Professional Development

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, West Virginia, New Mexico, South Carolina, and Florida, CE Broker #50-1223. Your certificate is valid in all states.

Payment: The registration fee for this test is FREE for STN members and \$24.95 for nonmembers.

STN members can take JTN CE for free using the discount code available in the members-only section of the STN website. Use the discount code when payment is requested during the check-out process.

DOI: 10.1097/JTN.000000000000746